Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00187928
Status:
COMPLETED
Last Update Posted:
2011-10-05
First Post:
2005-09-15
Brief Title:
Study to Determine the Efficacy and Safety of Adjunctive Topiramate in the Treatment of Obsessive-Compulsive Disorder
Sponsor:
University of Florida
Organization:
University of Florida
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Parallel Group Study to Determine the Efficacy and Safety of Adjunctive Topiramate in the Treatment of Obsessive-Compulsive Disorder
Status:
COMPLETED
Status Verified Date:
2011-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if a drug called topiramate is safe and effective as an add-on therapy in the treatment of Obsessive-Compulsive Disorder OCD Topiramate is an investigational drug for OCD which means it has not been approved by the US Food and Drug Administration FDA Topiramate has been approved as an add-on therapy for adults and children with partial onset seizures or generalized tonic-clonic seizures and for patients 2 years of age and older with a severe form of epilepsy called Lennox-Gastaut Syndrome
Up to 96 subjects will be enrolled in this study This study consists of three phases WashoutScreening Phase Double-Blind Phase and Taper Phase The total expected length of your participation in the study is approximately four months
Up to 96 subjects will be enrolled in this study This study consists of three phases WashoutScreening Phase Double-Blind Phase and Taper Phase The total expected length of your participation in the study is approximately four months
Detailed Description:
This is a multicenter outpatient randomized double-blind placebo-controlled parallel-group study designed to evaluate the safety and efficacy of adjunctive topiramate in treating subjects with OCD The study consists of a washoutscreening phase a double-blind treatment phase of 12 weeks a taper period of approximately 7 days Upon successful completion of the washoutscreening phase subjects will be randomized into 1 of 2 treatment groups topiramate up to 400 mgday or placebo A placebo control will be used to establish the frequency and magnitude of changed in clinical endpoints that may occur in the absence of active treatment
During the double-blind phase subjects will be seen weekly for the first two weeks and then every other week for the remainder of the double-blind phase Study medication will be titrated over the 8-week titration period up to 400mgday or the subjects maximum tolerated dose After the titration period the dose will remain stable for the maintenance period during which visits will occur every 14 days At the completion of the maintenance period subjects will taper their study medication over the next 7 days
This study will be conducted in up to 96 subjects with a diagnosis of OCD with an onset at least 1 year prior to screening supported by the SCID-I Forty-eight subjects will be assigned to topiramate and 48 will be assigned to placebo
During the double-blind phase subjects will be seen weekly for the first two weeks and then every other week for the remainder of the double-blind phase Study medication will be titrated over the 8-week titration period up to 400mgday or the subjects maximum tolerated dose After the titration period the dose will remain stable for the maintenance period during which visits will occur every 14 days At the completion of the maintenance period subjects will taper their study medication over the next 7 days
This study will be conducted in up to 96 subjects with a diagnosis of OCD with an onset at least 1 year prior to screening supported by the SCID-I Forty-eight subjects will be assigned to topiramate and 48 will be assigned to placebo
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None